Heritas Capital’s newly launched Growth Fund III backs Holmusk in latest strategic investment round alongside Novartis (dRx Capital) and Northwell Holdings
Holmusk, a leading global data science and digital health company building the world’s largest Real-World Evidence (RWE) platform for behavioral health, today announced the closing of a strategic investment round. The round included new investors Novartis (dRx Capital) and Northwell Holdings, the venture investment arm of Northwell Health, as well as initial investors Optum Ventures and Health Catalyst Capital.
Heritas Capital first led Holmusk’s Pre-Series A raise, and continued to back Holmusk in this strategic investment round via its newly launched Heritas Growth Fund III. The new funding round enables Holmusk to expand its global operations, as well as deepen its investment in its proprietary technology and growth of its data asset to better harness and analyze behavioral health real-world data to accelerate drug development and data-driven medicine.
“Heritas Capital is pleased to continue backing Holmusk alongside Novartis’ dRx Capital, Northwell Holdings, Optum Ventures and Health Catalyst Capital, making it our second follow-on investment since we first led Holmusk’s US$9.75 million Pre-Series A round in 2018, and joined its US$21.5 million Series A round in 2020. As Holmusk continues to develop its proprietary technology and grow its data assets, we believe that the company is uniquely positioned to drive evidence-based behavioural healthcare amidst growing underserved patient needs made more acute by the COVID-19 pandemic,” said Chik Wai Chiew, CEO and Executive Director of Heritas Capital.
Read more on Holmusk’s latest fund raise in the company’s press release.